Can canagliflozin decrease epicardial fat in patients with type 2 diabetes mellitus?


eMediNexus    17 January 2018

A study was performed to determine whether canagliflozin can reduce the thickness of epicardial adipose tissue, that is associated with insulin resistance and is a risk factor for coronary artery disease. The results published in the Diabetology and Metabolic Syndrome journal showed that this drug decreased the epicardial adipose tissue thickness in patients with type 2 diabetes mellitus (from 9.3 ± 2.5 to 7.3 ± 2.0 mm). This effect is independent of its impact on lowering blood glucose, indicating that canagliflozin may be helpful in preventing cardiovascular complications in this patient population.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.